Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
Real-time Estimate Cboe Europe  -  05/23 07:59:06 am EDT
555.00 CHF   +0.98%
05/18Lonza Opens New Facility for Kodiak Sciences' Retinal Diseases Drug
MT
05/09Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates
MT
05/09LONZA GROUP AG : Ex-dividend day for final dividend
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza JV Bacthera, Seres to Jointly Produce Potential Gut Infection Treatment

11/10/2021 | 03:43am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
CHR. HANSEN HOLDING A/S 0.08% 523.2 Delayed Quote.1.51%
LONZA GROUP AG 0.91% 555.2 Delayed Quote.-27.84%
SERES THERAPEUTICS, INC. 4.69% 3.57 Delayed Quote.-57.14%
All news about LONZA GROUP AG
05/18Lonza Opens New Facility for Kodiak Sciences' Retinal Diseases Drug
MT
05/09Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates
MT
05/09LONZA GROUP AG : Ex-dividend day for final dividend
FA
05/09LONZA GROUP AG : Ex-dividend day for Distribution from share premium account
FA
05/06EuroAPI gains on market debut after spin-off from Sanofi
RE
05/05LONZA GROUP AG : Dividends
CO
05/05LONZA GROUP AG : Proxy Statments
CO
04/29LONZA : to Divest its Quakertown Site Specialized in Particle Size Reduction; Business to ..
PU
04/29Investor group led by Derek Hennecke, TJ Higley, Mark Bamforth, Bill Mitchell and other..
CI
04/26Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody using ..
AQ
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 152 M 6 307 M 6 307 M
Net income 2022 1 064 M 1 091 M 1 091 M
Net cash 2022 423 M 433 M 433 M
P/E ratio 2022 38,3x
Yield 2022 0,60%
Capitalization 40 774 M 41 796 M 41 796 M
EV / Sales 2022 6,56x
EV / Sales 2023 5,84x
Nbr of Employees 16 218
Free-Float 98,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 549,60 CHF
Average target price 796,79 CHF
Spread / Average Target 45,0%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation
Werner J. Bauer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-27.84%41 796
MODERNA, INC.-46.35%54 195
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567
ALNYLAM PHARMACEUTICALS, INC.-22.00%15 980